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Aim  of the  study:  To  determine  the  content  values  that 2 separate  juries  of individuals  consider  to  be
important  in  making  decisions  about  resource  allocation  in  cancer  care.
Methods:  Two  citizens’  juries  were  established  through  random  and  stratiﬁed  sampling  of  the population
of  Northern  and Southern  Alberta  respectively.  Four  deliberative  sessions  were  run  identically  in both
juries.  Juries  participated  in exercises,  in  small  groups  as well  as  in plenary.  In  an exercise  in which  they
had  to select  5 out  of  10 cancer  technologies  for  funding,  the  juries  separately  identiﬁed  the  factors  they
considered  to  be important  for  resource  allocation  decision-making.
Results:  Socioeconomic  measures  between  the 2  juries  of  16  individuals  did  not  differ  signiﬁcantly.  The
juries  independently  arrived  at an  identical  list  of  content  values  that they  deemed  important  to  them  to
have  included  in  decision-making  processes.  These  were:  number  of  patients  who  could  beneﬁt,  current
health  state,  prognosis  without  the  technology,  health  outcome  with  the technology,  age,  and  dependents.
They  also  identiﬁed  “levels”  of  these  values,  2 for number  of  patients  (many,  few),  3 for  current  health
state  (severely,  mildly  and  moderately  ill),  3  for  prognosis  without  technology  (a few  weeks,  2 years  and
5  years  for  survival),  3 for  health  outcome  with  the  technology  (full  functioning,  sufﬁcient  functioning,
insufﬁcient  functioning),  2  for age  (old,  young)  and 2 for dependents  (yes, no).
Conclusion:  Given  appropriate  design  and  delivery,  Citizens’  Juries  can  deliberate  on  complex  health  issues
and reach  similar  conclusions.
ublis©  2014  The  Authors.  P
ntroduction
Over the past 2 decades, resource allocation decision-making
n developed countries has moved from a consideration of primar-
ly technical factors to the recognition that various other factors
eed to be incorporated into the decision process. While the tech-
ical factors usually relate to aspects of the competing demands
or resources (e.g., details of the speciﬁc health programs being
onsidered), it has become clear that decision-making in speciﬁc
ontexts requires the consideration of values as well [1–3]. This is
articularly accentuated in cancer care. For example, cost contain-
ent in cancer care has been referred to as a “moral issue”, and
here are calls for a more open and participatory process for mak-
ng choices [4]. It is also recognized that an acceptable deﬁnition of
he value of cancer treatments does not exist [5]. Finally, the con-
lusion has been reached in Great Britain (based on criteria used
∗ Corresponding author. Tel.: +1 780 492 908.
E-mail addresses: tanias@ualberta.ca (T. Staﬁnski), mccabe1@ualberta.ca
C. McCabe), menon@ualberta.ca (D. Menon).
ttp://dx.doi.org/10.1016/j.jcpo.2014.07.002
213-5383/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
by NICE to make decisions on oncology drugs) that not using actual
social values while making decisions may  have signiﬁcant health
and ﬁnancial implications [6].
“Values” have been deﬁned and categorized in various ways.
Kenny and Joffres [7] group them into terminal values (the goals
that the decision is to achieve), procedural values (related to the
decision-making process itself), and content values (the criteria and
principles employed). Clark and Weale [8] focus on process val-
ues (similar to procedural values above) and content values (which
relate to factors considered in the decision-making process). These
authors also propose that values that are incorporated into resource
allocation decision-making ought to be “. . .the same values as
those held by the population served by the healthcare system in
question”. This begs the question, how are these values to be deter-
mined?What do we know?
Since the late 1970s, a number of empirical studies have
reported on eliciting content values (i.e., factors considered
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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mportant for decision-making) from individuals and groups of
ndividuals. They have varied widely, in the methods of elicita-
ion, the speciﬁc populations involved, and the exact questions
ddressed. The approaches used to try and obtain an idea of the
alues that people consider to be important in making resource
ecisions have included self-administered questionnaires [9–20],
eb-based surveys [21], in-person interviews [22–29], and in an
arly study, a citizens’ jury approach [30]. These studies have been
escribed and compared in a 2011 review by Staﬁnski et al. [31].
ore recently, a participatory approach was used with a stand-
ng technology advisory committee in the province of Ontario in
anada [32], a mixed-methods approach in South Korea [33] and
 survey in Great Britain [6], all intended to elicit values held by
roups of people.
These studies have collectively concluded that there appears to
e a set of criteria that different groups believe to be important in
onsidering resource allocation in health care. However, typically,
he individual studies have focussed on a limited number of criteria
hen considering the views of groups of people. As well, the clear
ationale for who  “the public” comprised is not always explicated.
n this paper we report research into the content values that should
e used to inform resource allocation speciﬁcally in cancer care.
n designing the study we  explicitly sought to recruit respondents
ho were representative of the population affected by the decisions
hich the values would inform.
he objectives of this study
. To determine the content values that citizens of a Canadian
province (Alberta) would consider important for consideration
in resource allocation in cancer care
. To compare these values in two different samples of Alberta’s
population
. To obtain, through deliberative discussions with citizens, what
they consider to be meaningful different levels of each value
Building on the existing literature, the study was designed with
he following stipulations:
The group of citizens selected for the study must be socio-
demographically representative of the general population of
Alberta; this reﬂects the requirement that the values decision-
makers incorporate into decisions must reﬂect those of the
population they serve [8].
The process of engagement by which citizens’ views are elicited
must be deliberative in nature; this is elaborated on later in this
paper.
The process of engagement must include an educa-
tional/informational component, so that the participants
can engage in informed deliberations.
Participants must have to make choices between programs, and
must be able to defend their choices.
The study must be conducted in two different regions of the
province, under identical conditions, to study consistency of
views across the province.
Reporting of the study followed the Consolidated Criteria for
eporting Qualitative Research (COREQ) checklist [34].
aterials and methodshoice of method of engagement
There are numerous deliberative methods that have been
pplied in health care, and the appropriate method will dependcer Policy 2 (2014) 81–88
on the purpose of the deliberation. For example, Abelson et al. [35]
have concluded that “the design of procedurally fair and legitimate
processes that provide opportunities for meaningful involvement,
shared learning and the consideration of a range of views – the pil-
lars of deliberative methods” requires a small group of citizens.
This is one rationale for the choice of the Citizens’ Jury as the
approach to the elicitation of content values and resource allocation
in this study. The citizens’ jury has attracted considerable interest
from healthcare decision-makers [36–38]. Citizens’ juries, like legal
juries, are based on the idea that “once a small sample of the pop-
ulation has heard the evidence, its subsequent deliberations can
fairly represent the conscience and intelligence of the general pub-
lic” [39]. They typically involve 12–16 individuals who are selected
to be broadly representative of their community. Charged with
addressing 1 or more complex questions, they meet over a 2–4 day
period, during which they hear from expert ‘witnesses’ who repre-
sent a broad range of perspectives, engage in deliberations among
themselves, and come up with a common ground answer [36].
Therefore, in contrast to traditional opinion polls, surveys, focus
groups, and interviews (where information ﬂow is one way), citi-
zens’ juries attempt to seek ‘more informed’ public views (through a
multidirectional ﬂow of information among jurors and witnesses).
Findings from external evaluations of citizens’ juries are sparse, but
positive. Regarding fairness and competence, juror deliberations
have been shown to demonstrate rational, logical ﬂows of thought
that build upon previous arguments. They also reveal a shifting of
views from primarily self-interested to more socially aware ones
[40–43] It has also been demonstrated that individuals who  were
involved in a citizens’ jury retained the conclusions they reached
as a result of the deliberations, i.e., their positions on the topic are
not transient [44].
Selection of the juries
Two juries of 16 individuals each were selected to broadly rep-
resent the population of Northern Alberta and Southern Alberta
(totalling approximately 1.8 million people), respectively as fol-
lows.
For each jury, fourteen hundred individuals were selected ran-
domly (using a random number generator) from a commercially
prepared database of registered telephone numbers (Survey Samp-
ling International©). In addition, 100 randomly selected cellular
phone numbers from each area were selected to ensure adequate
sampling of individuals in the 18–34 year old range. This sample
size was calculated from response rates for previously published
citizens’ juries, which ranged from 2 to 40% [37]. A letter inform-
ing individuals of the study, and eliciting expressions of interest in
participating was sent to each address. Information letters and con-
sent forms were then mailed to those who responded positively.
To reduce volunteer bias, an honorarium of $400 was  offered to
jurors, as well as reimbursement of all jury-related expenses; this
is considered standard practice in citizens’ juries [45].
Individuals who were willing and able to participate were
interviewed by 2 researchers (experienced in qualitative research
methods) using a pre-tested interview script. Survey questions
were designed to collect information on socio-demographic data
(age, gender, ethnicity, education, household income and employ-
ment status) as well as information on potential afﬁliations with
health-related special interest/patient advocacy groups and/or
employment as a healthcare professional in a healthcare deliv-
ery organization or government. The latter were used as exclusion
criteria for the study, as the intent was  to elicit the views of the gen-
eral public or ‘ordinary citizens’ (i.e., individuals with no particular
axe to grind or whose voices might otherwise not be heard). Purpo-
sive and stratiﬁed sampling was then used to select the 16 jurors
as follows: eligible respondents were ﬁrst grouped according to
of Cancer Policy 2 (2014) 81–88 83
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Table 1
List of technologies used in decision simulation exercise.
Technology Indication
Endobronchial ultrasound-guided
transbronchial ﬁne needle biopsy
Determining the spread of lung
cancer to areas between the lungs
Bortezomib (proteasome inhibitor
treatment)
Recurrent multiple myeloma
Laser therapy Removal of fetal tumours
Brachytherapy (localized internal
radiation)
Unresectable liver cancer
BRCA 1 and 2 genetic test Screening for presence of genes
linked to hereditary breast cancer
Cementoplasty (injection of acrylic
bone cement)
Relief from pain and stabilization
of bone with malignant cavities
Cryotherapy (use of liquid nitrogen
to freeze and destroy cells)
Localized kidney cancer
Human papillomavirus vaccine Protect boys and men  from
catching and spreading genital
HPV to female sexual partners
Chemotherapy wafer Delivery of anticancer drugs
directly into sites of removed
glioma (type of brain tumour)T. Staﬁnski et al. / Journal 
ender and age; then stratiﬁed by level of education and household
ncome (before taxes); then purposively selected to match the age,
ender and socioeconomic distribution of the Alberta population,
ased on census data from Statistics Canada. Ethnic backgrounds
including First Nations) were also taken into account. This samp-
ing was used because it is well known that such socio demographic
actors inﬂuence health, and so differences in them between the
uries had to minimized in order to generate data that might oth-
rwise be biased [46]. When several respondents with the same
haracteristics were identiﬁed, random sampling (using a random
umbers table) was used to choose among them. In the following,
he Northern Alberta (Southern Alberta) Jury is referred to as NA
SA) jury.
rganization of the juries
As is standard procedure for citizens’ juries, an advisory commit-
ee was created, comprised in this case of 2 senior health executives
ith experience in healthcare resource allocation in Alberta (in
ancer and in health services generally), a practising oncologist
nd a senior researcher. Based on previous experience and pub-
ished evaluations of citizens’ juries, a 2½ day jury session was
lanned [44,47]. The advisory committee also helped to select
expert witnesses’ representing various stakeholder perspectives:
n oncologist, a senior cancer service delivery decision maker, a
enior health service delivery decision maker, an ex-senior gov-
rnment decision maker responsible for funding policies and a
ancer patient advocate (3 male, 2 female). These expert witnesses
ere the same for both juries. Cancer technologies were chosen
s the ‘case study’ for presentations and jury deliberations for 3
ain reasons: (1) the public has a general familiarity with cancer
nd its implications; (2) cancer technologies span the entire care
athway (including prevention, screening, curative treatments, and
alliative interventions) and, thus, encourage trade-off discussions
round the range of beneﬁts or effects various types of health ser-
ices may  have on different patient populations; and (3) much of
he recent public criticism over access to quality health care has
een related to cancer technologies (mainly high-cost pharmaceut-
cals) [5,48,49].
onduct of the juries
The 2 juries were run in exactly the same way. Eight sessions
ere conducted over the entire period of each jury. The sessions
ere organized such that at the end of the fourth session, the
urors were to be able to identify the values that they considered
mportant for them to consider during resource allocation decision
aking. This paper reports on the outcomes of these ﬁrst 4 sessions.
ession 1
A facilitator conducted an “ice-breaker” session for the jurors
nd witnesses. Introductory presentations were made by the
xpert witnesses on the need for priority-setting in healthcare
nd decision-making challenges in cancer care. The use of citi-
ens’ juries as a means of obtaining public views was described
o the jurors by the principal investigator of the project, who  is an
xperienced health services/policy researcher.
ession 2
“A day in the life” presentations by the 5 ‘expert witnesses’. This
as followed by a simulated decision making exercise by these
itnesses, who were presented with 5 cancer technologies: (1)
evacizumab for glioblastoma multiforme, a common and fatal
ype of primary brain tumor, (2) brachytherapy for breast cancer,
3) robotic surgery for localized prostate cancer, (4) faecal immuno-
hemical tests for colorectal cancer screening, and (5) implantableGemtuzumab (monoclonal
antibody treatment)
Relapsed acute myeloid leukemia
in children
drug delivery systems for cancer pain. These technologies rep-
resented funding requests in the province at the time and had
been recommended by the advisory committee. The information
provided to the witnesses was similar in content and type as is
frequently contained in ministerial brieﬁng documents. It had pre-
viously been pilot-tested for readability with a convenience sample
of the public who  had agreed to the initial survey, but had not
been selected for the juries. The expert witnesses were asked to
describe the characteristics of the patient populations (which are
content values) for each technology that they considered during
the deliberations.
Session 3
In 3 small groups (roughly balanced on age, gender and edu-
cation), the jury acted as a provincial coverage committee and
undertook a decision simulation exercise, to select 5 out of 10 tech-
nologies (see Table 1). The cost of each technology was assumed
to be the same. Each group was  facilitated by a researcher (with
master’s degree level preparation in health research) who offered
clariﬁcation on the choice task and ensured active participation
from all group members. The groups then reconvened in plenary to
compare choices and discuss characteristics they had considered.
They then compiled a list of these ranked in order of importance. In
addition, through further deliberative discussions, they identiﬁed
distinct categories or levels within characteristics which they felt
shaped their choices (e.g., age: young versus old).
Session 4
In order to illustrate the implications of “no” decisions, including
public and patient responses to them, and to test the robustness of
the juries’ choices of the 5 technologies in Session 3, scenarios were
developed on 3 technologies that were not unanimously selected by
the juries for funding: (1) a newspaper article about a child denied
‘last chance’ therapy for leukemia; (2) a letter to the Board Chair
of the provincial health services delivery organization from a nurse
with unresectable liver cancer, caused by hepatitis C contracted
through work, whose only option other than “gruelling” systemic
alternatives, was  brachytherapy, a treatment available in neigh-
boring provinces; and (3) a letter to the Premier from a prominent
neurosurgeon condemning the province’s decision not to fund the
chemotherapy wafer for high grade glioma, a particularly “aggres-
sive and deadly form of cancer with few treatment options”. These
“appeals” to “do not fund” decisions were presented to the jury
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y 3 of the expert witnesses. At the end of the discussion, jurors
ere given the opportunity to change their minds (i.e., revisit and
evise the list of 5 technologies they selected to fund), in light of
he arguments presented.
nalysis of data
All jury sessions were digitally recorded and transcribed.
ranscripts were analyzed using content analytic and constant
omparison techniques to assess the ﬂow of arguments, assess
he extent to which all of the jurors’ views had been captured,
nd to systematically organize data into a structured format [34].
o accomplish this, data (chunks of information) were sorted,
rranged, and coded using dedicated qualitative research software
NVivo® 8). To minimize observer bias, 2 researchers trained in
ualitative methods independently reviewed all of the transcripts,
nd then met  to compare ﬁndings and reconcile differences [50].
In addition to these qualitative analyses, quantitative methods
ere used to compare the two juries. Differences in response rates
o invitations to participate between the two juries were assessed
sing Pearson’s Chi-Square Test [51,52]. Given the small sample
izes of the actual juries, Fisher’s Exact Tests were used to detect sta-
istically signiﬁcant differences in age, gender, ethnicity, education
evel, household income (before taxes), employment status, and
eographic location of residence (all categorical variables) between
he two juries [50].
esults
ury composition
A total of 684 replies accompanied by completed consent forms
ere received within 2 weeks of the mail-out in Northern Alberta,
nd 701 in Southern Alberta. The difference was not statistically sig-
iﬁcant (p-value = 0.56). All respondents completed the telephone
creening survey. Approximately 60% of the non-respondents had
ot received the original invitation (letters were returned by the
ost ofﬁce, marked as ‘no known address’, ‘change of address’ or
no forwarding address’). Socio-demographic characteristics of the
6 individuals selected for each of the 2 juries are presented in
able 2. Slight variations in the distribution of age, education and
ousehold income between juries were evident, but none reached
tatistical signiﬁcance at the 95% level.
ury sessions
ession 1
The ‘ice breaker’ session, and dinner with the expert witnesses
nd researchers resulted in the jurors reaching a level of comfort
ith them and each other. The jurors took advantage of the oppor-
unity to question presenters in this session, who described the
eed for priority-setting in health care, the conﬂicting challenges in
ancer care, and the use of the citizens’ jury as a means of eliciting
he views of the public. This session resulted in a better under-
tanding on the part of the jurors (based on their verbal feedback)
f how provincial funding decisions are made, and of the trade-
ffs inherent in this, both within health care and across all public
ectors.
ession 2
Each expert witness described his/her roles in the provincialealth system and the types of decisions they faced. The pressures
hey confronted in making resource allocation decisions (between
atient populations with different characteristics) were described
nd discussed with the jurors. In this way, the jury acquired a bettercer Policy 2 (2014) 81–88
understanding of the complexities of resource allocation decision-
making, particularly in an area such as cancer care, which impacts
almost every individual at some time or other. Then as a panel,
and facilitated by the principal investigator, the expert witnesses
discussed the 5 technologies presented to them. The objective of
this exercise was  not to select a single technology, but to deliber-
ate around what they would consider while making a choice. The
witnesses came up with characteristics of the particular patient
populations that would use the technology, e.g., the number of peo-
ple who  might beneﬁt and severity of the condition being managed
by the technology, and of the potential impact of the technology,
e.g., on survival, quality of life and costs. It was also suggested that
there should be an attempt made to ensure a range of services
(e.g., preventive and palliative) be made available through such pro-
cesses. The jurors actively engaged in discussion with the witnesses
on what the relevant considerations ought to be. The deliberations
served as an example of how the jurors could subsequently engage
in simulated decision-making exercises.
Session 3
(a) Selection of technologies: Four of the ﬁve cancer technologies
selected for funding were identical between juries: endobronchial
ultrasound-guided transbronchial ﬁne needle biopsy; a genetic test
for hereditary breast cancer; cryotherapy for localized kidney can-
cer; and cementoplasty for bone pain. The rationale for choices was
similar across juries, with both expressing a desire to fund tech-
nologies that represented a wide range of types of interventions
(e.g., screening or prevention, diagnosis, treatment, and supportive
care). (Please see Appendix A row 1 for quotations from individual
members (identiﬁed by a number) of the two Juries).
Both juries spent considerable time deliberating over their ﬁfth
choices. Though their deliberations covered similar issues and argu-
ments, the juries arrived at different decisions. For example, both
juries felt that the HPV vaccine could beneﬁt a large number of
individuals. Please see Appendix A row 2 for comments.
They also raised points related to ‘lifestyle’ choices as risk fac-
tors for certain cancers, such as liver cancer. In both juries, this
topic led to an active, lengthy debate among jurors. Some argued
that funding priorities should focus on patient populations whose
“unhealthy behaviours” had not contributed to their health state.
Please see Appendix A row 3.
Others presented the ‘slippery slope’ argument, consistently
raising the example of obesity. Please see Appendix A row 4.
Both juries also discussed the issue of entitlement to healthcare
as taxpayers. Please see Appendix A row 5.
In the end, the NA jury chose to fund the HPV vaccine for boys,
reiterating the importance of funding technologies that they felt
beneﬁtted the greatest number of individuals. In contrast, the SA
jury selected brachytherapy for unresectable liver cancer, citing
severity of illness and the lack of “good” alternative treatments as
the main reasons.
(b) Identiﬁcation of important factors: Both juries compiled sim-
ilar lists of factors or characteristics of patient populations they
thought inﬂuenced their choices. The list comprised the following
factors. Appendix B provides quotations from both Juries on each
factor.
(1) Number of patients who  could beneﬁt (Appendix B, row 1).
(2) Current health state (severity of illness) (Appendix B, row 2).
(3) Prognosis without treatment (Appendix B, row 3).
(4) Health outcomes – quality of life (Appendix B, row 4).
(5) Age (Appendix B, row 5).
(6) Dependents (care-giving responsibilities) (Appendix B, row 6).
(7) Personal responsibility for illness (Appendix B, row 7).
(8) Health outcomes – length of life (Appendix B, row 8).
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Table  2
Comparison of socio-demographic proﬁles of the 2 juries.
Characteristic Number of jurors (%)* p Value*
Southern Alberta Jury Northern Alberta Jury
Gender
Male 8 (50%) 8 (50%)
0.64Female 8 (50%) 8 (50%)
Age
18–24  2 (13%) 2 (13%)
1.00
25–34  2 (13%) 2 (13%)
35–44  2 (13%) 2 (13%)
45–54  4 (26%) 3 (19%)
55–64 3 (19%) 3 (19%)
65–74 2 (13%) 2 (13%)
>74  1 (6%) 2 (13%)
Education (highest level)
<High school 1 (6%) 1 (6%)
1.00
High school 4 (25%) 5 (31%)
Post-secondary diploma 4 (25%) 4 (25%)
Undergraduate degree 4 (25%) 4 (25%)
Graduate degree 3 (19%) 2 (13%)
Annual household income ($ Cdn, before taxes)
<$25,000 2 (13%) 3 (19%)
1.00
$25,000–$45,000 4 (25%) 4 (25%)
$46,000–$70,000 3 (19%) 3 (19%)
$71,000–$100,000 4 (25%) 3 (19%)
>$100,000 3 (19%) 3 (19%)
Employment status
Employed 12 (75%) 12 (75%)
1.00Unemployed 2 (13%) 2 (13%)
Retired 2 (13%) 2 (13%)
Ethnicity
Asian 2 (13%) 1 (6%)
0.60Caucasian 13 (81%) 13 (81%)
First  Nations (Aboriginal) 1 (6%) 2 (13%)
s
i
e
t
6
l
r
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CGeographic location
Urban 12 (75%) 
Rural 4 (25%) 
On further discussion in plenary, the jurors agreed that “per-
onal responsibility for the illness” should not be a consideration
n resource allocations, and “health outcomes” were already cov-
red by “prognosis without treatment” and “health outcome (with
echnology)”. This reduced the list to 6 factors. Juries ranked these
 factors from most important to least important, producing two
ists which were almost identical (see Table 3).
On further deliberation in the jury as a whole, agreement was
eached on the levels that each of these factors could be divided
nto. The results are presented in Table 4.ession 4
Importantly, when jurors were “interrogated” by ‘witnesses’ on
heir selection of technologies for funding, they stood their ground,
hoosing not to revise their decisions. They explained that “it is
able 3
omparison of rankings of factors/patient characteristics between juries.
Factor/patient characteristic Rank (from most to least important)
Southern Alberta
Jury
Northern Alberta
Jury
1. Number of patients who
could beneﬁt
1 1
2. Current health state 2 2
3. Prognosis without treatment 4 3
4. Health outcome (with
technology)
3 4
5. Age 5 5
6. Dependents 6 612 (75%)
0.664 (25%)
not that we  don’t value what those other technologies could do
for people, we  do . . . it is just that we think these ones are more
worthwhile”; “we would have loved to fund them all, but there
wasn’t enough money and some difﬁcult decisions had to be made
. . . we thought we would be giving up the least by not funding these
ones”; and “2 months of life is not a helluva lot over something that
could ease pain for many cancer patients, I don’t think so, not on
my watch”.
Discussion
This study was conducted with three main objectives. The ﬁrst
objective was to understand what Albertans considered to be the
important “content values” to be included while making decisions
on resource allocations in health care. These values have been
determined and documented above, focussing on cancer care. Fur-
ther, the study was  repeated in two separate parts of the province,
using identical approaches, and this yielded essentially the same
results. This addresses the second objective. Finally, through their
deliberations, the juries were able to come to agreement about the
“levels” of each of the factors that might weigh differently in choice
decisions; this was the third objective of this study.
The other stipulations of the study, presented in the section “The
Objectives of This Study” have also been met. In order to understand
the views of the population of the province of Alberta, the partic-
ipants for the study were sampled from this population and can
be seen as representative of Albertans generally. Recent research
points to the need for healthcare decisions made in a system to
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Table  4
Summary of factors/patient characteristics and categories/levels around which distributive preferences were elicited.
Factor/patient characteristic Categories/levels Description
1. Number of patients
who could beneﬁt
Many N/A
Few
2.  Current health state Severely ill Unable to perform daily activities; in extreme pain or discomfort; depressed
Moderately ill Unable to perform some daily activities; in moderate pain or discomfort; mildly depressed
Mildly ill Occasionally unable to perform a few daily activities; in mild pain; not depressed
3.  Prognosis without
the technology
A few weeks
Life expectancy
without treatment
2  years
5 years
4. Health outcome
(with technology)
Full functioning Health returns to normal (i.e., what it was before the illness)
Sufﬁcient functioning Health does not return to normal, but patients are able to perform daily activities
Insufﬁcient functioning Health improves, but does not return to normal and patients are not able to perform most daily activities
5.  Age Young Average age: 20–30 years
Old Average age: 60–70 years
6.  Dependents Yes Has care-giving responsibilities
No Does not have care-giving responsibilities
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oecognize the values of people within the system [7,8], and this
ondition is met  by our study. The choice of method of engag-
ng members of the public was modelled after the citizens’ jury,
hich is an intensive deliberative approach; deliberation was  stip-
lated as a requirement of this study. The early and continued active
ngagement of the expert witnesses provided a good information
ase which enabled the jurors to discuss in a more informed man-
er than otherwise would have been possible. Another stipulation
elated to opportunity costs – by having to choose between tech-
ologies, jurors were forced to make trade-off decisions. This is an
nherent part of real-world decision-making and ensures that the
ecommendations are expressions of preferences, in the economic
ense of the word [53]. Finally, the experiment was repeated in 2
eographical regions, which was the last stipulation.
More speciﬁcally, the exercise of selecting 5 technologies for
unding from 10 technologies forced sub-groups of the juries to
eliberate in detail and evidently openly about the pros and cons of
electing (or not selecting) a particular technology. Through these
eliberations, they were able to change their positions based on
hat others in the sub-group had to say. This process, which fol-
owed a similar discussion among the expert witnesses enabled
urors to articulate their views on what really mattered, and to con-
erge on a number of factors that they considered most important.
Additionally, by being placed in the situation where they were
nterrogated by the expert witnesses, jurors were forced to confront
heir own decisions, and deal openly with the perceived negative
mplications of a “do not fund” decision. Although they were free
o change their initial decision, in reality the process reinforced the
mportant criteria they had considered in making their choice in
he ﬁrst place.
It is interesting to note that both juries arrived at the same list of
 characteristics that they considered to be the most important. The
ankings of these were almost identical between the 2 juries. Given
hat the juries were sampled from the two halves of the province of
lberta (so as to be representative of the population in each half),
his would imply that these 6 factors could be seen as being impor-
ant to Albertans in general. This could well carry a message to
olitical and health system decision makers in the province.
Despite agreeing on the 6 speciﬁc factors, the 2 juries did not
gree on which technologies they would select from a given set.
his implies that the jurors were probably weighting the different
ontent values differently, depending on the choices they faced.
his suggests that merely obtaining a list of ranked priorities (in this
r any other manner) and using these ranks to make priority-settingdecisions will not truly reﬂect what people might do, if they were
in the role of deciding. It also suggests that the relative weighting
of these values will change from circumstance to circumstance.
The content values identiﬁed by the Alberta juries are similar
to sets of values reported in the literature, e.g. severity of illness
[31,33], current health state [31], immediate need [31], age [31],
lifetime health [31], pre-existing health state [31), personal respon-
sibility for illness [31], care-giving responsibilities [31], health gain
[31,33], and socioeconomic status [33]. These values are not all
mutually “orthogonal” or independent, so it is not surprising to
ﬁnd some overlap. As well, some of the differences could be due to
overriding societal values.
Two other points are worthy of mention. First, the response
to the original invitations to be considered for participation in
the Juries was surprisingly good. Nearly two-thirds of all individ-
uals who received the invitation (i.e., excluding those that were
returned because of address or other issues) accepted it. Clearly this
reﬂects the fact that there is signiﬁcant interest among the ordinary
citizens of Alberta in being involved in health care resource alloca-
tion matters. There may  be many reasons for this high response, but
one plausible explanation is that this reﬂects a desire of ordinary
citizens to have more of a say in how government decides to spend
public funds.
Finally, the set of 6 content values and the levels of each (see
Table 4) provide a starting point to develop an applied choice anal-
ysis, such as a discrete choice experiment. Additionally, we believe
having level descriptors which describe severity, and include men-
tal health is a strength of the study (see Table 4). This is the next
step in trying to understand relative priority rankings between the
combinations of factors and levels.
The main limitation to this study most likely results from what
is also probably a strength – the fact that the same group of
researchers and expert witnesses participated in both juries. While
this reduced the possible variation in quantity and types of infor-
mation presented to the jurors, it also left open the possibility that,
based on the experience during the ﬁrst jury, individuals might
have acted in somewhat different ways to the jurors during the
second jury. Attempts were made to minimize any “leading” by
the team and experts by asking that presentations were scripted to
the largest extent possible, and that no leading questions be asked
of jurors. This also hopefully resulted in minimal “advocacy” on
the part of the experts. Another limitation might be in how jurors
interpreted terms, such as health “before the illness”, particularly
if multiple morbidities are involved.
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onclusion
Findings from this study suggest that given appropriate design
nd delivery, different citizens’ juries held on a common, complex
ealthcare topic, such as resource allocation decision-making for
ew health technologies, appear to yield similar results. It has been
emonstrated that this approach is a reasonable and rational one to
ngage ordinary citizens in a meaningful way in decision-making
atters of public import. However, since the Jury approach is time,
abour, and cost-intensive, it would be appear to be best suited to
ddressing high-level issues that governments may  be grappling
ith.
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ppendix A.
1 “We  wanted to make sure we spread the funding over
many different types of technologies and people”
(NAJ1)
“We  thought it would be a good idea to invest in a bit
of  everything – like, you know, prevention and
treatment” (SAJ2)
2 “Of the ones left, this one [the HPV vaccine] could
probably help the greatest number of individuals . . . so
the money would be going the furthest” (NAJ6)
“Well, the HPV vaccine has the biggest group in terms
of numbers when you consider all boys in Alberta”
(SAJ1)
3  “You know, if you go out drinking every night, smoke a
pack a day, you should know better, and you should
have to accept the consequences – like ‘sorry, there are
other people who got sick through no fault of their
own, so they are ahead of you”’ (NAJ10)
“While we don’t know what causes a lot of cancer, we
do  know what causes some, like liver cancer. When
there is a shortage of funds, we need to be wise about
our  money, and people who  live that way  may  not take
care of themselves after we  help them, so that would
mean we wasted money that we could have used to
help somebody else” (SAJ3)
4  “How do we know that drinking or smoking was  the
cause – maybe they were obese? I mean, can we really
say  that because you did those things you got cancer
and it is your fault? The fact is, [we] really don’t know
– there is no magical test. Maybe it is about obesity, in
which case, we wouldn’t bother treating 50% of the
population. I don’t think we  really want to go there”
(NAJ1)
“This opens up a whole new can of worms  . . . what
about obesity then? Should we  be weighing people
and saying to them, ‘forget it, you are too fat, we  aren’t
treating you’ . . . wow, I wouldn’t want to live in a
society like that” (SAJ16)
5 “I pay taxes on the cigarettes I smoke and on my
paycheque.  . .that should more than pay for any
healthcare I might need down the road” (NAJ7)
“We  all pay taxes, whether we smoke or don’t smoke,
eat right or don’t eat right. . .so the healthcare system,
which we pay for through our taxes, shouldn’t
discriminate against people either” (SAJ4)
[
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Appendix B.
1 “What kind of numbers are we talking about – a few
patients or a lot?” (NAJ1)
“How many people could be helped?” (SAJ8)
2  “How sick are they now?” (NAJ2)
“What is their current health like. . .are they [patients]
already suffering?” (SAJ15)
3 “What happens if we don’t act now?” (NAJ1)
“How long do they [patients] have?” (SAJ5)
4  “How does the technology help with giving patients
some quality of life – you know, some dignity?” (NAJ9)
“Will patients be able to do, like, daily activities – like
take care of themselves, or enjoy their families?” (SAJ2)
5  “How old are they [patients]?” (NAJ11)
“Have they already had a long life?” (SAJ13)
6  “Would they [patients] probably have kids or people
who they needed to take of?” (NAJ6)
“Would there likely be a young family left behind?”
(SAJ1)
7  “Could bad choices have contributed to them getting
sick?” (NAJ10)
“What about lifestyle – what role did that play?” (SAJ9)
8  “Would it extend life and for how long?” (NAJ10)
“How much more time would it buy them?” (SAJ15)
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